4.8 Article

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy

Journal

CELL REPORTS
Volume 21, Issue 5, Pages 1240-1252

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2017.10.018

Keywords

-

Categories

Funding

  1. Japan Society for the Promotion of Science (KAKENHI) [25713034, 15K15339, 16H05321]
  2. National Center of Neurology and Psychiatry [29-4]
  3. NIH [NS058901, NS098819]
  4. Grants-in-Aid for Scientific Research [15K15339, 25713034, 16H05321] Funding Source: KAKEN

Ask authors/readers for more resources

Myotonic dystrophy types 1 (DM1) and 2 (DM2) are dominantly inherited neuromuscular disorders caused by a toxic gain of function of expanded CUG and CCUG repeats, respectively. Although both disorders are clinically similar, congenital myotonic dystrophy (CDM), a severe DM form, is found only in DM1. CDM is also characterized by muscle fiber immaturity not observed in adult DM, suggesting specific pathological mechanisms. Here, we revealed upregulation of the interleukin-6 (IL-6) myokine signaling pathway in CDM muscles. We also found a correlation between muscle immaturity and not only IL-6 expression but also expanded CTG repeat length and CpG methylation status upstream of the repeats. Aberrant CpG methylation was associated with transcriptional dysregulation at the repeat locus, increasing the toxic RNA burden that upregulates IL-6. Because the IL-6 pathway is involved in myocyte maturation and muscle atrophy, our results indicate that enhanced RNA toxicity contributes to severe CDM phenotypes through aberrant IL-6 signaling.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available